Novartis divests anti-infectives brands to Samara Capital
Global pharma major Novartis AG today said it has divested some of its anti-infectives brands mainly catering to the women's healthcare to private equity firm Samara Capital for an undisclosed sum.
The Switzerland-based firm had earlier this year divested its Regestrone and Pregachieve brands in India in women's healthcare to Ahmedabad-based Torrent Pharmaceuticals.
"Samara Capital acquired from Novartis AG, for an undisclosed amount, the rights to the trademarks Cofvector, Monkezin and Glyred along with an exclusive license to the trademarks Curam, Foristal and Gretacal, for use in India", a Novartis spokesperson said in a emailed response to
(This article has not been edited by Zeebiz editorial team and is auto-generated from an agency feed.)
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.